기업
Eli Lilly Inks $1.3B RNA-editing Therapeutics Deal with Rznomics
by Sungmin Kim
Co-development of precision RNA therapeutics for inherited hearing loss treatment
▲Seong-Wook Lee, CEO of Rznomics
Eli Lilly Signs $1.3 Billion Global Licensing Deal with Rznomics for RNA-editing Therapeutics Based on Trans-splicing Ribozyme Technology.
Rznomics announced on 15th that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed.
“We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation,” said Dr. Seong-Wook Lee, CEO of Rznomics. “This partnership validates our trans-splicing ribozyme platform and opens the door to treating previously intractable diseases with precision RNA therapeutics. Together with Lilly, we aim to accelerate the development of transformative therapies for patients around the world.”
This partnership marks a significant milestone for Rznomics as it seeks to expand its presence in the global biotech arena. For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas.
